Royalty Report: Drugs, Disease, Therapeutic – Collection: 3782

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • HIV / AIDs
  • Diagnostic
  • Technical Know How
  • Biotechnology
  • HPV
  • Immune
  • Vaccine

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3782

License Grant
A University Research Foundation won, by settlement, an up-front payment and royalties on a drug to treat hepatitis.

The intellectual property was taken from the University and includes possible treatments for herpes, HIV, and other viruses.  The University sued the company who was gaining from the patents, asserting that a former professor had founded the Licensee company and made off with University intellectual property.  The settlement applies to worldwide sales of telbivudine, an antiviral drug used to treat Hepatitis B.

Field of Use
The rights granted apply in the use of LdT for treating Hepatitis B virus infections (HBV infections).

IPSCIO Record ID: 3939

License Grant
Chief executive officer, in his individual capacity, the University of Montpellier and CNRS entered into a settlement Agreement with UAB, University of Alabama at Birmingham Research Foundation, or UABRF, and Emory University.

Pursuant to this settlement Agreement, all contractual disputes relating to patents covering the use of certain synthetic nucleosides for the treatment of the HBV virus and all litigation matters relating to patents and patent applications related to the use of ß-L-2’-deoxy-nucleosides for the treatment of HBV assigned to one or more of the Licensees and which cover the use of Tyzeka®/Sebivo® (telbivudine) for the treatment of HBV have been resolved.

Field of Use
The field of use relates to the medical industry.

IPSCIO Record ID: 233457

License Grant
The Parties now revise certain terms and conditions of the Agreement to give effect to the Parties’ agreement that Swiss Licensee will take over control of Development, Commercialization and Manufacture of the LdT Product and related matters, on a worldwide basis.

With this amendment, the HBV License now reads as follows for the LdT License
– Subject to the terms and conditions of this Agreement,  Licensor grants to The Swiss Licensee a right and license, with the right to grant sublicenses as permitted, under Licensors rights in the Licensors Intellectual Property and in the Joint Intellectual Property to manufacture, have made, use, market and promote, import and export, offer for sale, sell and distribute the LdT Product in the Field within the Licensees Territory during the applicable Country Terms for the LdT Product.   The license granted to Licensee in this subsection shall be exclusive, even with respect to Licensor as to the Licensees Territory.

With this amendment,  EU Countries and Licensee takes over control of Development, Manufacture and Commercialization worldwide, and books sales.
– Licensee will pay royalties for the US Territory, the Major EU Countries and the Rest of World Territory.
– the Parties will terminate the existing Supply Agreement and the Commercial Manufacturing Agreement, along with some changes to other agreements.
– Licensor grants to Licensee a license to Manufacture worldwide.

This agreement has pediatric exclusivity terms and a non-exclusive grant back to Licensor.

License Property
LdT Product Patent Rights means those Licensor LdT Product Patent Rights, where Licensor is the patent owner, co-owner or licensee, including for the avoidance of doubt, pediatric exclusivity terms.

The patents cover
– Methods of Treating Hepatitis Delta Virus Infection with Beta-L-2- Deoxynucleosides
– Crystalline and Amorphous Forms of B-L-2-Deoxythymidine
– B-L-2-Deoxynucleosides for the Treatment of Lamivudine-Resistant
– Industrially Scalable Nucleoside Synthesis
– Synthesis of Beta-L-2- Deoxynucleosides
– B-L-2-Deoxypyrimidine Nucleosides for the Treatment of Hepatitis B, and,
– Methods of Manufacture of 2-Deoxy-B-L-Nucleosides

Field of Use
Licensor is a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases. The Company’s current focus is on diseases caused by hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

IPSCIO Record ID: 243429

License Grant
This agreement is for the use of Herpes Simplex Virus Type 2 Antigens as Immunoprophylaxis or Immunotherapy to prevent or treat HSV Infections in Humans.

The University grants a Co-Exclusive license and a Tri-Exclusive license under the Licensed Patents to manufacture, have manufactured on Companys behalf, use, offer to sell or sell, offer to lease or lease, import, or otherwise offer to dispose or dispose of Licensed Products in the Field of Use in the Territory.

Tri-Exclusive means, with respect to a license, that such license may only be granted to Company and two Third Parties.

License Property
The research relates to the use of Herpes Simplex Virus Type 2 (HSV2) antigens as immunoprophylaxis or immunotherapy to prevent or treat HSV infections in humans.

Genital herpes is a sexually transmitted disease caused by the herpes simplex viruses HSV-1 or HSV-2, and in extreme cases, can appear in and about the eyes, esophagus, trachea, brain, and arms and legs.

Field of Use
The Field of Use means therapy that is administered to prevent or treat HSV2 infection.

IPSCIO Record ID: 6565

License Grant
The Licensor today announced the execution of a License Agreement for elvucitabine, the Company’s nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of both hepatitis B virus (HBV) infection and human immunodeficiency virus (HIV) infection with the Licensee.

The exclusive License grants the Licensee the right, through its Chinese joint venture with Tianjing Institute of Pharmaceutical Research, to clinically develop and commercialize elvucitabine in mainland China, Hong Kong, and Taiwan. In Phase 2 clinical trials elvucitabine has demonstrated to be safe and well tolerated and to be efficacious in both HBV and HIV infected patients. Under the terms of the Agreement, the Licensee, through a subLicense Agreement with its Chinese joint venture, T & T Pharma Co., Ltd., formed with Tianjing Institute of Pharmaceutical Research  will assume all development and regulatory responsibility and associated costs for elvucitabine.

Field of Use
The rights granted apply to the Pharmaceutical Market relating to healthcare.

IPSCIO Record ID: 65389

License Grant
The company has entered an agreement with the University to license various patents and know-how to use CRISPR/Cas9 technologies for developing a possible cure for hepatitis B virus (HBV) and human papilloma virus (HPV).  This license allows the company to develop and potentially commercialize a cure for HBV utilizing the underlying patents and technologies developed by the universities.
License Property
CRISPR sequences are expressed in bacteria and match viral DNA in a way that defends against viruses. Cas is a related immune defense mechanism that works with CRISPR to slice through a viruss DNA and eliminate it.
Field of Use
This agreement pertains to the drug industry relating to the hepatitis B virus and human papilloma virus.

IPSCIO Record ID: 66074

License Grant
The company has an exclusive license from the University for use of certain inventions and technology related to inhibitors of hepatitis C virus that were jointly developed by both the University and companys employees.  The University agrees to add to the Licensed Patents and Licensed Technology University’s rights to any patent, patent application, invention, or technology application that is based on technology disclosed within three (3) years of March 7, 2013.
License Property
CRISPR sequences are expressed in bacteria and match viral DNA in a way that defends against viruses. Cas is a related immune defense mechanism that works with CRISPR to slice through a viruss DNA and eliminate it.
Field of Use
This agreement pertains to the drug industry relating to the inhibitors of hepatitis c virus.

The company is excited to explore the CRISPR/Cas technologies to potentially develop the first virus targeted genome modifying treatment that may be able to provide a cure for human papilloma virus (HPV) and hepatitis B virus (HBV).

IPSCIO Record ID: 204323

License Grant
Korean Licensor grants an exclusive license, with the right to sublicense, under all Licensor Patent Rights and Know-How, including, without limitation, Licensors rights in Licensors Inventions, to develop, make, have made, use, register, offer to sell, sell, export and import the Compounds and Program Products in the Licenses Territory in the Anti-HBV Field.
License Property
The Program Product means any pharmaceutical formulation containing a Compound for administration to humans to treat chronic Hepatitis B Virus or HBV infection.

Hepatitis B virus, or HBV, infection is a growing global health problem that can cause both acute and chronic viral infections.

The patents are for Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.

IP relates to potential commercialization LB80380 (ANA380), a Phase II nucleotide analog for the treatment of chronic hepatitis B virus infection.

Field of Use
LB80380 (ANA380) is a nucleotide analog currently in Phase II clinical trials for the treatment of chronic HBV infection. The compound has exhibited activity in vitro against both HBV typically found in untreated patients and also HBV variants that demonstrate resistance to treatment with the nucleotide analog lamivudine, which is a currently commercialized therapy for HBV. Preclinical studies have demonstrated significant activity against HBV, low potential for drug interactions and good tolerability in a range of preclinical toxicology studies. Based on clinical trials to date, LB80380 (ANA380) appears to offer the potential for once daily dosing.

IPSCIO Record ID: 243430

License Grant
This amendment addresses the sublicense consideration.

The original agreement is for the use of Herpes Simplex Virus Type 2 Antigens as Immunoprophylaxis or Immunotherapy to prevent or treat HSV Infections in Humans.

The University grants a Co-Exclusive license and a Tri-Exclusive license under the Licensed Patents to manufacture, have manufactured on Companys behalf, use, offer to sell or sell, offer to lease or lease, import, or otherwise offer to dispose or dispose of Licensed Products in the Field of Use in the Territory.

Tri-Exclusive means, with respect to a license, that such license may only be granted to Company and two Third Parties.

License Property
The research relates to the use of Herpes Simplex Virus Type 2 (HSV2) antigens as immunoprophylaxis or immunotherapy to prevent or treat HSV infections in humans.
Field of Use
The Field of Use means therapy that is administered to prevent or treat HSV2 infection.

IPSCIO Record ID: 3900

License Grant
Pursuant to an exclusive license agreement, the Company was granted exclusive Licenses in perpetuity for technologies developed by Licensor for the virus types HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies.

The Company and Licensor have agreed, in principle, to an amendment to the existing Licensing Agreement to include additional virus types among the virus types the Company is permitted to manufacture, use, and offer for sale, and, Licensor has permitted the Company to use its nanomaterials to develop treatments for Dengue viruses, Ebola/Marburg viruses, and viruses causing viral Conjunctivitis (a disease of the eye), until such time as the Company and Licensor can complete an amendment to the Licensing Agreement to include these additional virus types we are permitted to manufacture, use and offer for sale.

Field of Use
The rights granted apply to the healthcare industry relating to life-threatening viral infections.

IPSCIO Record ID: 257474

License Grant
The original agreement is an exclusive license under Licensor patent rights and know-how to develop, make, have made, use and sell Licensed products in the Territory.
License Property
With this amendment, Licensed products shall also mean Treatment vaccines.  Treatment vaccines shall mean a bulk or finished vaccine.

The parties wish to further amend the Agreement to provide that Merck shall have rights to vaccine products for the treatment of patients infected with Human Immunodeficiency Virus and Hepatitis B Virus.

Field of Use
The field of use is for the treatment of Human Immunodeficiency Virus (HIV-1) and/or diseases caused by infection with HIV-I in humans and Hepatitis B Virus (HBV) and/or diseases caused by infection with HBV in humans, which utilizes the Technology or technology which is developed by Licensor during and as a result of the Research Collaboration Program.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.